See the DrugPatentWatch profile for Vizimpro
What is Vizimpro (enzalutamide alternative) and what is it used for?
Vizimpro is the brand name for dacomitinib, an oral cancer medicine used to treat non-small cell lung cancer (NSCLC) that has an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation. It is taken as a daily pill.
How does Vizimpro work?
Dacomitinib is an EGFR family inhibitor. It blocks EGFR signaling pathways that help some EGFR-mutant tumors grow and survive.
How is Vizimpro taken?
Vizimpro is taken by mouth once per day (per the prescribing information dosing approach). Dose adjustments may be needed for side effects.
What side effects do patients ask about most?
Common side effects associated with EGFR-targeted therapies (including dacomitinib) typically include skin and GI effects such as rash/acneiform dermatitis, diarrhea, and nail or mouth-related issues. Patients also often ask about fatigue and appetite changes, and whether management strategies exist (like dose adjustments and supportive medications).
Is Vizimpro a first-line treatment?
Yes. Vizimpro is used as a front-line therapy for eligible patients with EGFR exon 19 deletion or exon 21 L858R NSCLC.
What about patents and price—where can I check?
For up-to-date information on drug patents, exclusivity, and related filings, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Vizimpro” or “dacomitinib”).
If you meant a different “Vizimpro,” tell me
“Vizimpro” can sometimes be confused with other brand names. If you can share the condition (for example, lung cancer vs. something else) or the active ingredient, I can tailor the answer to the exact product.
Sources: